Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

Inclusion Criteria: To enroll in Cohort A, a subject must:

• Be 45-80 years of age (inclusive) at the time of screening.
• Be recently diagnosed with primary colorectal cancer or advanced adenoma with plans tosurgically remove the target lesion. To enroll in Cohort B, a subject must:
• Be 45-80 years of age (inclusive) at the time of screening.
• Be planning to undergo a screening colonoscopy within 30 days after providing signedinformed consent.

Exclusion Criteria: To enroll in Cohort A, a subject must NOT have:

• Inflammatory bowel disease (IBD)
• Personal or family history of colorectal cancer syndromes or other hereditary cancersyndromes To enroll in Cohort B, a subject must NOT have:
• Personal history of colorectal cancer, colorectal adenoma or aerodigestive tractcancer.
• Personal or family history of Familial adenomatous polyposis (FAP).
• Personal or family history of Hereditary non-polyposis colorectal cancer syndrome (HNPCC or Lynch Syndrome).
• Positive fecal occult blood testing (FOBT) within the previous 6 months.
• Positive fecal immunochemical testing (FIT) in the previous 6 months.
• Colorectal resection for any reason other than sigmoid diverticular disease.
• Overt rectal bleeding within the previous 30 days.
• Personal history of any cancer diagnosed <5 years prior.
• Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) andCrohn's disease.
• Colonoscopy within the previous 9 years.
• Barium enema, computed tomographic colonography, or sigmoidoscopy within the previous 5 years.
• ≥ 2 first-degree relatives who have been diagnosed with colorectal cancer (Note: Firstdegree relatives include parents, siblings and offspring).
• 1 first-degree relative with CRC diagnosed before the age of 60.
• Have participated or be currently participating in a clinical research study in whichan experimental medication has been administered during the 30 days up to andincluding the date of providing informed consent or may be administered through thetime of the colonoscopy.
• Have a medical condition which, in the opinion of the investigator, should precludeenrollment into the study.